

Apr 23, 2020

Use of tracer dyes to label neural projections to lower urinary tract organs

 In 1 collection

DOI

dx.doi.org/10.17504/protocols.io.w2xfgfn

Janet R Keast¹, Peregrine B Osborne¹

¹University of Melbourne


SPARC

Tech. support email: info@neuinfo.org



Janet R Keast

University of Melbourne



Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.w2xfgfn>

Protocol Citation: Janet R Keast, Peregrine B Osborne 2020. Use of tracer dyes to label neural projections to lower urinary tract organs. **protocols.io** <https://dx.doi.org/10.17504/protocols.io.w2xfgfn>



License: This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: January 13, 2019

Last Modified: November 27, 2023

Protocol Integer ID: 19255

Keywords: retrograde tracing, tract tracing, neural circuits, urinary tract organs this protocol, proximal urethra in an experimental adult male, bladder body, proximal urethra, bladder trigone, urinary tract organ, lower urinary tract, use of tracer dye, tracer dye, methods of anesthesia, anesthesia, female rat, surgical environment, rat, animal experimentation, organ, neural projection, experimental adult male

Abstract

This protocol is used to visualise sensory and autonomic neurons innervating the bladder body (dome), bladder trigone or proximal urethra in an experimental adult male or female rat. The protocol is performed under anesthesia and should incorporate all local requirements for standards of animal experimentation, including methods of anesthesia, surgical environment, and post-operative monitoring and care.

Materials

MATERIALS

- ⊗ Neuros syringe **Hamilton Company Catalog #65460-02**
- ⊗ Fluorogold **Merck MilliporeSigma (Sigma-Aldrich) Catalog #39286**
- ⊗ Fast Blue **Polysciences, Inc. Catalog #17740-1**
- ⊗ Isoflurane **Zoetis Catalog #10015516**
- ⊗ Fluorogold **Fluorochrome**
- ⊗ Lacrilube **Ellar Laboratories**

Troubleshooting

Preparation for surgery

- 1 Prepare tracer dye solutions: Fluorogold or Fast Blue (each 2% w/v in sterile water).
- 2 Anesthetise animal (2.5% isoflurane in oxygen, or as required for maintenance)
- 3 Apply eye lubricant and place animal on heated pad.
- 4 Shave and clean the ventral abdomen.

Surgery

- 5 Perform a midline incision in the skin and then the muscle, then gently move organs to visualise the required injection site.
- 6 Microinject sterile tracer solution at the selected injection site using a Hamilton Neuros Syringe attached to a 33G needle. At each injection site, hold the needle in place for ~5 seconds after ejection of the dye, to enable the dye to spread to the underlying tissue. This also minimises leakage.

Note

Injections into the bladder body (dome) are made bilaterally on dorsal and ventral aspects; total volume ~ 5 µl. Single injections are made into the bladder trigone or dorsal aspect of the proximal urethra (maximum 0.3 µl per injection).

- 7 Wash all injection sites with sterile saline.
- 8 Close the muscle and skin using approved procedures. Administer analgesics and monitor animal during postoperative period as per local approved procedure.

Tissue harvesting



- 9 To analyse tracer dye distribution in ganglia or the injection site, 5-14 days after surgery, fix animals by intra-cardiac perfusion, then remove tissues of interest for further study.

Note

For studies of the lower urinary tract innervation, these tissues would typically include dorsal root ganglia (DRG) from L1, L2, L6 and S1 spinal levels and the pelvic ganglia (synonym, major pelvic ganglia). It is also recommended that the lower urinary tract tissues are also removed for microscopic validation of the tracer injection site.